2015 Small-Cap Biotech Watchlist Announced

Release of The Life Sciences Report's 2015 Small-Cap Biotech Watchlist marks the third year we have brought together a team of analysts at the Biotech Showcase to compile a basket of stocks based on catalyst prospects for the coming year. This year's experts are some of the leading stock watchers in the space: Mara Goldstein, managing director and senior healthcare analyst at Cantor Fitzgerald; Reni Benjamin, head of equity research and senior healthcare analyst at H.C. Wainwright & Co.; Joe Pantginis, head of biotechnology research and senior research analyst at ROTH Capital Partners; and George Zavoico, managing director of equity research at MLV & Co. The companies in the Watchlist are poised for transformational events, which readers can monitor year-round in real time using the Portfolio Tracker.

Biotech Showcase attendees can hear the analysts' thoughts on the Watchlist companies at an exclusive panel discussion on Jan. 13, or sign up below to receive a summary of the conversation and updates on company progress throughout the year.

And the companies are:

The Life Sciences Report

SMALL-CAP BIOTECH WATCHLIST 2015

Logo	Company	Market Cap	Analyst	Therapy Area / Product
	Applied Genetic Technologies Corp.* (AGTC:NASDAQ)	$348M	Mara Goldstein, Cantor Fitzgerald	Genetic therapies for rare diseases including X-linked juvenile retinoschisis, achromatopsia and alpha-1 antitrypsin deficiency
	Can-Fite BioPharma Ltd.* (CANF:NASDAQ)	$34M	Reni Benjamin, H.C. Wainwright & Co.	Synthetic, specific agonists targeting the A3 adenosine receptor, including CF101, an oral drug in development for rheumatoid arthritis and psoriasis
	Lion Biotechnologies Inc.* (LBIO:NASDAQ)	$163M	Joe Pantginis, Roth Capital Partners	TIL Technology (tumor infiltrating lymphocytes); immunotherapeutic treatments targeting metastatic melanoma and solid tumors
	MEI Pharma Inc.* (MEIP:NASDAQ)	$129M	Joe Pantginis, Roth Capital Partners	Cancer treatment through inhibitors including pracinostat (hematological cancers), ME-344 and PWT143
	Oncothyreon Inc.* (ONTY:NASDAQ)	$160M	Reni Benjamin, H.C. Wainwright & Co.	Cancer therapies using small molecules and immunotherapies, including tecemotide, ONT-380 and ONT-10
	OncoSec Medical Inc.* (ONCS:NASDAQ)	$110M	Reni Benjamin, H.C. Wainwright & Co.	Electroporation platform technologies targeting skin cancers, including the OncoSec Medical System (OMS) and ImmunoPulse
	Peregrine Pharmaceuticals Inc.* (PPHM:NASDAQ)	$226M	George Zavoico, MLV & Co.	Treatment of cancer using monoclonal antibodies, including bavituximab, and the Tumor Necrosis Therapy (TNT) platform
	Sunesis Pharmaceuticals Inc.* (SNSS:NASDAQ)	$143M	Mara Goldstein, Cantor Fitzgerald	Cancer therapies targeting solid tumors and blood cancers including Qinprezo (vosaroxin)
	Synta Pharmaceuticals Inc.* (SNTA:NASDAQ)	$329M	George Zavoico, MLV & Co.	Inhibition of molecular chaperones in cancer, including ganetespib
	TG Therapeutics Inc.* (TGTX:NASDAQ)	$615M	Joe Pantginis, Roth Capital Partners	Cancer treatments using monoclonal antibodies and checkpoint inhibitors, including TGR-1101 (ublituximab) and TGR-1202
	Threshold Pharmaceuticals Inc. (THLD:NASDAQ)	$203M	George Zavoico, MLV & Co.	Induction of hypoxia in a variety of solid tumors and hematological cancers; lead compound is TH-302
	Verastem Inc.* (TSTM:NASDAQ)	$237M	Mara Goldstein, Cantor Fitzgerald	Inhibition of cancer stem cell pathways; compounds include VS-6063 (mesothelioma, lung and ovarian cancer)
Information in this chart was pulled from company websites and Yahoo Finance. Companies with an * are not affiliated with Streetwise Reports.